763 related articles for article (PubMed ID: 26245379)
41. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
42. Effective application of bicelles for conformational analysis of G protein-coupled receptors by hydrogen/deuterium exchange mass spectrometry.
Duc NM; Du Y; Zhang C; Lee SY; Thorsen TS; Kobilka BK; Chung KY
J Am Soc Mass Spectrom; 2015 May; 26(5):808-817. PubMed ID: 25740347
[TBL] [Abstract][Full Text] [Related]
43. Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.
Marmolejo-Valencia AF; Martínez-Mayorga K
J Comput Aided Mol Des; 2017 May; 31(5):467-482. PubMed ID: 28364251
[TBL] [Abstract][Full Text] [Related]
44. To probe interaction of morphine and IBNtxA with 7TM and 6TM variants of the human μ-opioid receptor using all-atom molecular dynamics simulations with an explicit membrane.
Sader S; Anant K; Wu C
Phys Chem Chem Phys; 2018 Jan; 20(3):1724-1741. PubMed ID: 29265141
[TBL] [Abstract][Full Text] [Related]
45. Correlated Motions of Conserved Polar Motifs Lay out a Plausible Mechanism of G Protein-Coupled Receptor Activation.
Mitra A; Sarkar A; Szabó MR; Borics A
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33946214
[TBL] [Abstract][Full Text] [Related]
46. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.
Che T; Majumdar S; Zaidi SA; Ondachi P; McCorvy JD; Wang S; Mosier PD; Uprety R; Vardy E; Krumm BE; Han GW; Lee MY; Pardon E; Steyaert J; Huang XP; Strachan RT; Tribo AR; Pasternak GW; Carroll FI; Stevens RC; Cherezov V; Katritch V; Wacker D; Roth BL
Cell; 2018 Jan; 172(1-2):55-67.e15. PubMed ID: 29307491
[TBL] [Abstract][Full Text] [Related]
47. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor.
Rasmussen SG; Choi HJ; Fung JJ; Pardon E; Casarosa P; Chae PS; Devree BT; Rosenbaum DM; Thian FS; Kobilka TS; Schnapp A; Konetzki I; Sunahara RK; Gellman SH; Pautsch A; Steyaert J; Weis WI; Kobilka BK
Nature; 2011 Jan; 469(7329):175-80. PubMed ID: 21228869
[TBL] [Abstract][Full Text] [Related]
48. An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.
Groer CE; Tidgewell K; Moyer RA; Harding WW; Rothman RB; Prisinzano TE; Bohn LM
Mol Pharmacol; 2007 Feb; 71(2):549-57. PubMed ID: 17090705
[TBL] [Abstract][Full Text] [Related]
49. Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.
Zhang Y; Sham YY; Rajamani R; Gao J; Portoghese PS
Chembiochem; 2005 May; 6(5):853-9. PubMed ID: 15776407
[TBL] [Abstract][Full Text] [Related]
50. Structural insights into binding specificity, efficacy and bias of a β
Masureel M; Zou Y; Picard LP; van der Westhuizen E; Mahoney JP; Rodrigues JPGLM; Mildorf TJ; Dror RO; Shaw DE; Bouvier M; Pardon E; Steyaert J; Sunahara RK; Weis WI; Zhang C; Kobilka BK
Nat Chem Biol; 2018 Nov; 14(11):1059-1066. PubMed ID: 30327561
[TBL] [Abstract][Full Text] [Related]
51. Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors.
Strahs D; Weinstein H
Protein Eng; 1997 Sep; 10(9):1019-38. PubMed ID: 9464566
[TBL] [Abstract][Full Text] [Related]
52. Graded activation and free energy landscapes of a muscarinic G-protein-coupled receptor.
Miao Y; McCammon JA
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12162-12167. PubMed ID: 27791003
[TBL] [Abstract][Full Text] [Related]
53. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
Zhang Q; Purohit V; Yoburn BC
Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
[TBL] [Abstract][Full Text] [Related]
54. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains.
Zhorov BS; Ananthanarayanan VS
Arch Biochem Biophys; 2000 Mar; 375(1):31-49. PubMed ID: 10683246
[TBL] [Abstract][Full Text] [Related]
55. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
56. Molecular mechanisms of fentanyl mediated β-arrestin biased signaling.
de Waal PW; Shi J; You E; Wang X; Melcher K; Jiang Y; Xu HE; Dickson BM
PLoS Comput Biol; 2020 Apr; 16(4):e1007394. PubMed ID: 32275713
[TBL] [Abstract][Full Text] [Related]
57. Structural and functional interactions between six-transmembrane μ-opioid receptors and β2-adrenoreceptors modulate opioid signaling.
Samoshkin A; Convertino M; Viet CT; Wieskopf JS; Kambur O; Marcovitz J; Patel P; Stone LS; Kalso E; Mogil JS; Schmidt BL; Maixner W; Dokholyan NV; Diatchenko L
Sci Rep; 2015 Dec; 5():18198. PubMed ID: 26657998
[TBL] [Abstract][Full Text] [Related]
58. Conserved Mechanism of Conformational Stability and Dynamics in G-Protein-Coupled Receptors.
Bhattacharya S; Salomon-Ferrer R; Lee S; Vaidehi N
J Chem Theory Comput; 2016 Nov; 12(11):5575-5584. PubMed ID: 27709935
[TBL] [Abstract][Full Text] [Related]
59. Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor.
Cong X; Campomanes P; Kless A; Schapitz I; Wagener M; Koch T; Carloni P
PLoS One; 2015; 10(8):e0135998. PubMed ID: 26280453
[TBL] [Abstract][Full Text] [Related]
60. GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors.
Emtage AL; Mistry SN; Fischer PM; Kellam B; Laughton CA
J Biomol Struct Dyn; 2017 Sep; 35(12):2604-2619. PubMed ID: 27532213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
